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ABSTRACT
Objective: Innovative application of quality by design (QbD) technique for simultaneous estimation of levofloxacin and ambroxol hydrochloride (HCL) 
in bulk and its pharmaceutical dosage form using reverse phase-high-performance liquid chromatography (RP-HPLC) method.
Method: A method has been developed for the separation of levofloxacin and ambroxol HCL using RP-HPLC on C18 column (250 4.6 mm, 5 ml) with 
ultraviolet detection at 306 nm. Experimental designs were applied for multivariate optimization of the experimental conditions of RP-HPLC method. 
Three independent factors: Acetonitrile content in the mobile phase composition, buffer pH, and flow rate were used to design mathematical models. 
Here, central composite design (CCD) experimental design was used to study the response surface technique and to study in depth the effects of 
these independent factors. Derringer’s desirability function was applied to simultaneously optimize the retention time of last eluting peak (ambroxol 
hydrochloride) and resolution between levofloxacin and ambroxol hydrochloride.
Result and Discussion: The predicted optimum assay condition consisted of acetonitrile, potassium dihydrogen phosphate buffer (pH 5.00; 
potassium dihydrogen phosphate), and methanol in a proportion of 20:70:10% v/v, respectively, as the mobile phase at a flow rate of 1.2 ml/minute. 
Using this optimum condition, baseline separation of both drugs with good resolution and a run time of <5 minutes were achieved. The optimized 
assay condition was validated according to the ICH guidelines to confirm specificity, linearity, accuracy, and precision.
Keywords: Levofloxacin, Ambroxol hydrochloride, Experimental design, Response surface methodology, Derringer’s desirability, Quality by design 
approach.
INTRODUCTION
Levofloxacin hemihydrate [1,2] is a synthetic broad-spectrum 
antibacterial agent. The chemical name is (-)-(S)-9-fluoro-2,3-dihydro-
3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-
1,4benzoxazine-6-carboxylic acid hemihydrates Fig. 1. Levofloxacin 
is active against both Gram-positive and Gram-negative bacteria and 
acts as a bactericide by inhibiting the enzymes such as DNA gyrase 
and topoisomerase IV. Topoisomerase IV is necessary to separate DNA 
that has been replicated (doubled) before bacterial cell division. With 
the DNA not being separated, the process is stopped, and the bacterium 
cannot divide. DNA gyrase, on the other hand, is responsible for 
supercoiling the DNA so that it will fit in the newly formed cells. Both 
mechanisms explained the amount of killing the bacterium.
Ambroxol hydrochloride (HCL) [3,4] is a potent mucolytic and 
mucokinetic. Ambroxol HCL is chemically Trans-4-[(2-amino-3, 
5-dibromobenzyl) amino]-cyclohexanol hydrochloride Fig. 2. Ambroxol 
is indicated as “secretolytic therapy in bronchopulmonary diseases 
associated with abnormal mucus secretion and impaired mucus 
transport. It promotes mucus clearance, facilitates expectoration, and 
eases productive cough, allowing patients to breathe freely and deeply.”
Moreover, the extensive literature survey revealed that there is no 
reverse phase-high-performance liquid chromatography (RP-HPLC) 
method available for simultaneous estimation of levofloxacin or 
ambroxol combination in the pharmaceutical dosage forms using 
experimental design approach quality by design (QbD). A few 
analytical methods [5-8] have been reported in the literature for the 
determination of levofloxacin or ambroxol alone or combination with 
other drugs biological fluids and pharmaceutical dosage forms. They 
include derivative spectrophotometric [9,10] methods and other 
methods such as HPLC with ultraviolet (UV) detection, HPTLC [11,12], 
and liquid chromatography with tandem mass spectrometry were also 
reported for the determination of ambroxol from human body fluids 
and pharmaceutical dosage form. Some analytical procedure has been 
reported for quantitative determination of levofloxacin and norfloxacin 
by capillary electrophoresis with electrochemiluminescence 
detection [13]. Recently, one article is published for validated high-
performance liquid chromatographic method for levofloxacin and 
ambroxol using Hypersil BDS C18 column (25 cm × 4.6 mm, 5 µm). 
The mobile phase constituted of Buffer:Acetonitrile:Methanol 
(650:250:100) at a flow rate of 1.0 ml/minutes. [14]. This method has 
a run time of more than 10 minutes as well as does not describe the 
design space (DS) [15] or interaction study of independent factors as 
per recent FDA guidelines [16].
Regulatory authorities such as FDA and ICH guidelines [17,18,19] 
are promoting and requesting the application of experimental design 
approach to understand chromatographic selectivity and support 
better method control, including method transfer. This prompted 
the researchers to adopt the experimental design in HPLC, and many 
papers were published related to this work [20-26]. The main objective 
of our work is to develop an improved RP-HPLC method suitable for the 
routine quality control of levofloxacin or ambroxol in a pharmaceutical 
industry and provide information on the sensitivity of chromatographic 
factors and their interaction effects on the separation characteristics. 
The optimization of chromatographic factors such as acetonitrile 
concentration in mobile phase, buffer pH, and flow rate are very 
complex that have a significant effect on chromatographic separation. 
All these independent factors can easily optimize using the design of 
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experiments that is called QbD approach. QbD is a systemic approach 
that includes multi-dimensional combinations and input variables using 
the design of experiment to obtain the optimum conditions with good 
assurance of quality. DS is generated through an experimental design 
that shows the flexible region, in which post-approval changes are not 
required during any of changes in the parameters (e.g., pH and % of 
organic modifier) (ICH Q8 (R2). When one needs to optimize more than 
one response (resolution, last retention time, and capacity factor of the 
drug peak) at a time, the use of derringer’s desirability function [27,28] 
is the best choice. Derringer’s desirability function was first used 
in chromatography by Deming to get better resolution and shorter 
analysis time as objective functions to get better separation quality. 
We have employed the same methodology for the development and 
optimization of a new HPLC method for the simultaneous estimation of 
levofloxacin or ambroxol from a bulk and tablet formulation.
EXPERIMENTAL
Materials
Levofloxacin and ambroxol working standards were received as gift 
samples from BAFNA Pharmaceuticals India. Disodium potassium 
hydrogen orthophosphate (analytical grade), methanol (HPLC grade), 
and acetonitrile (HPLC grade) (S.D Fine Chemical Pvt. Ltd., Mumbai, 
India) were used throughout these experiments. HPLC grade water 
was collected from the Milli-Q system. The marketed tablets (Livbest-
AM) used containing 500 mg of levofloxacin and 75 mg of ambroxol per 
tablet were manufactured by Piramal Healthcare Pvt. Ltd., India, and it 
is procured from the local market.
Instrumentation and chromatographic conditions: A Shimadzu HPLC 
system consists of an LC-20AD solvent delivery system (pump), SPD-
M20A photodiode array detector, Rheodyne injector with 20 μL loop 
volume, and LC-solution assisted for data collections and processing. 
The chromatographic separation was performed using phenomenex 
C18 150×4.6 mm, 5 m column, detection wavelength is 306 nm and run 
time is 10 minutes.
Software experimental design (rotatable central composite), 
desirability function, and data analysis calculations were performed 
using design expert (Version 7.0.1.0 Stat-Ease Inc., Minneapolis, MN, 
USA) trial version statistical software.
Preparation of phosphate buffer solution
About 6.8 g of potassium dihydrogen orthophosphate was dissolved 
in sufficient water (HPLC grade) with aid of sonicator. Then, add 
triethylamine (TEA) or orthophosphoric acid was used to adjusted the 
pH to 5.
Preparation of standard stock solution
About 100 mg of levofloxacin and 100 mg of ambroxol were accurately 
weighed and transferred into 100 ml volumetric flasks. The contents 
of the volumetric flask were dissolved in methanol (HPLC grade) to get 
1 mg ml of both levofloxacin and ambroxol. Working standard solution 
was freshly obtained by diluting the standard stock solution with 
mobile phase during the analysis time.
Chromatographic procedure
Chromatographic separations were carried out on a phenomenex 
(C18 150×4.6 mm, 5 m). A mixture of acetonitrile, potassium dihydrogen 
phosphate (pH-5, KH2PO4), and methanol (25:65:10) was used as the 
mobile phase. The pH of the buffer solution was adjusted by phosphoric 
acid (H3PO4) and TEA. The wavelength of 306 nm was used as detection 
at which both drugs gave good response.
Experimental design and response surface methodology (RSM)
The central composite design approach can be useful to optimize the 
separation and to help out in the development of better understanding 
of the interaction of several chromatographic factors on separation 
quality. The development of a QbD for selected drugs and finally 
reach the definition of its DS and optimization of method, the process 
could be illustrated in four steps (Scheme 1) to complete the method. 
The first step is to identify the goal of the intended method that 
depends on the types of the method developed such as for routine 
quality control assay method should be fast, accurate, and specific. 
Hence, we set the same goal for our assay method. The second step 
is the assessment of critical factors that affect on the critical quality 
attributes such as in HPLC resolution, run time, and capacity factor 
of peak. The third step is the creation of experimental design and 
mathematical model that expresses the relation between the factors 
and response. In this work, the important chromatographic factors 
were selected based on preliminary experiments and prior knowledge 
from the literature and optimized by a central composite design 
(CCD) experiment. A CCD design was employed to locate the optimum 
flow rate, mobile phase pH, % of organic modifier for separation by 
mapping the chromatographic response surface. Table 1 shows three 
chromatographic factors and levels selected, in which experimental 
condition was optimized.
To provide a rotatable CCD for three independent variables, a partial 
factorial design was combined with five replicates of center points and 
five axial points at an extreme level. The qualities of the fitted polynomial 
models were examined on the basis of the coefficient of determination 
R2. The position of the true optimum condition was recognized by 
applying Derringer’s desirability function, where responses were 
simultaneously optimized. The final step is to predict the response and 
DS from the polynomial equation. RSM is a mathematical and statistical 
technique valuable for analyzing problems where several independent 
Table 1: The experimental factors and levels used in central 
composite design
Factor Name Level(‑1) Level (0) Level(+1)
A Acetonitrile (%v/v) 20 25 30
B Buffer pH 4.5 5 5.5
C Flow rate (mL min-1) 0.8 1.0 1.2
Fig. 1: Levofloxacin hemihydrate
Fig. 2: Ambroxol hydrochloride
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variables such as column temperature, pH, and flow rate affect 
dependent variables or responses (e.g., resolution, capacity factor, and 
run time). This technique is used to simultaneously optimize the levels 
of these variables to attain the best system performance. RSM enables 
definition of quadratic models that accurately explain the response 
for all values of the chromatographic conditions in the experimental 
region. For calculation of quadratic regression model coefficients, each 
design variable must be studied, at least at three distinct levels and 
consequently, a CCD was used in this optimization study.
RESULTS AND DISCUSSION
Method development and optimization of levofloxacin and ambroxol 
are medium-polar analytes because of the amino group and 
fluoroquinolone moiety. Hence, reverse phase mode is more preferable 
than normal phase. Initially, we tried different reverse phase columns 
such as C18, cyano, and C8 for separation of both analytes. However, 
cyano column showed poor separation of both analytes while in C8, 
levofloxacin was eluting early with a broader peak shape. Therefore, 
we considered only C18 column for optimization study. The overlay UV 
spectra Fig. 3 of both drugs, which indicates that 306 nm is the optimum 
wavelength to detect levofloxacin and ambroxol with good response as 
well as minimum baseline noise.
The mobile phase pH is an important factor that drives the selectivity 
of the method due to differences in the pKa of molecules. Initial method 
development was tried on three different pH 4.5, 5.0, and 5.5 based 
on the literature report [17]. However, high-tailing (>2) was observed 
with levofloxacin at pH 5 and 5.5 and mild tailing at pH 4.5 due to the 
interaction between a positively charged solute (amine of levofloxacin) 
and a negatively charged silanol on the surface of silica stationary 
phase at pH 4.5 and 5.5. It is observed most often when using HPLC 
columns packed with stationary phases that have significant silanol 
activity. It is usually worse in a basic pH mobile phase than in an acidic 
pH mobile phase because pKa of silanol groups is around 3.5, therefore, 
above pH 3.5 silanol groups are in ionized form and ready to interact 
with 1, 2 amines. Therefore, TEA was added to inhibit levofloxacin 
peak tailing due to the interaction of a free silanol group. Mainly 
organic modifiers for reversed-phase include acetonitrile, methanol, 
and in some cases, tetrahydrofuran. Due to the high UV cut off as well 
as presence of peroxide impurities in tetrahydrofuran that affect the 
stability of analytes, hence tetrahydrofuran was avoided for selection 
of organic modifier. We have used acetonitrile because of its cost, good 
solubility in all buffers, and it acts as Lewis acid by donating hydrogen 
that improves the only C18 column for optimization study. Fig. 3 shows 
the overlay UV spectra of both drugs, which indicates that 308 nm is 
the optimum wavelength to detect levofloxacin and ambroxol with good 
response as well as minimum baseline noise.
Design of experiment and DS: The design matrix generated for the 
rotatable central composite design is shown in Table 2, and the system 
was fully optimized using the 15 experiments. This design is composed of 
a three level factorial design with 15 experimental runs. In this study, the 
levels of each factor were selected based on prior scouting experiments. 
Many more experiments would have been required if this method was 
optimized with the standard univariate approach. Initially, it was found 
that at below 0.8 ml/minutes flow rate peaks became broad and above 
1.2 ml/minutes proper separation was not observed. In the same way, ideal 
acetonitrile concentration was found in between 20% v/v and 30% v/v. If 
any C18 column works consistently at pH 5.0 that reduces the column shelf 
life, therefore, keeping this in mind, we tried to optimize the pH range in 
between 4.5 and 5.5. As can be seen in Table 2, the ranges of each factor 
were: Flow rate (0.8-1.2 ml/minute 1), buffer pH (4.5-5.5), and acetonitrile 
concentration (20-30% v/v). Here, our main goal is to develop the method 
with minimum run time as well as a good resolution between the peak 
of levofloxacin and ambroxol that facilitate the accurate quantification of 
drugs within a short period the results are shown in Fig. 4. Hence, retention 
time (Rt) of last eluting peak (ambroxol Rt), capacity factor, and resolution 
between two peaks (Rs) were taken as a response.
The statistical parameters obtained from analysis of variance for 
the regression models are listed in Table 3. Probability p<0.05 was 
obtained, implying that these models are significant. Adjusted R2 was 
well within the acceptable limits (R2>0.8) that show experimental 
model is good fit with polynomial equations. The adequate precision 
value is a measure of the ‘‘signal (response) to noise (deviation) ratio’’ 
that should be greater than four. In this study, the ratio was found to 
be greater than 15, which indicates an adequate signal, and therefore, 
the model is significant for the separation process. The reproducibility 
of the model depends on the coefficient of variation (C.V.) that is well 
within the limit of both responses (% C.V.<10) [28]. Table 3 illustrates 
the interaction term with the largest absolute coefficients among the 
fitted models is 0.61AC of Rt model. The positive interaction between A 
and C is statistically significant (p=0.001) for Rt.
The study reveals that changing the fraction of acetonitrile from low 
to high results in a rapid decline in Rt both at the low and high level 
of buffer pH. Further, at the low level of factor A and B, an increase in 
the flow rate results in a marginal decrease in the Rt of ambroxol Rt. 
Therefore, when acetonitrile concentration is set at its lowest level, 
Scheme 1: Graphical representation of method development flow using quality by design technique
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the buffer pH has to be at its lowest level to shorten the analysis time. 
Especially, this interaction is synergistic, as it led to a decrease in 
analysis time. The second response model T reveals that all factors affect 
moderately on the tailing of levofloxacin. To get a better understanding 
of the results, the perturbation plots are presented in  Fig. 5a-c. For an 
optimization design, this graph shows how the response changes as 
each factor moves from a chosen reference point, with all other factors 
held constant at the reference value. A steep slope or curvature in 
a factor indicates that the response is sensitive to that factor. Fig. 5b 
reveals that as acetonitrile concentration in mobile phase decreases, 
resolution between levofloxacin and ambroxol reduces due to decline 
in the interaction with free silanol groups of column.
DS was generated after processing all data using the modeling software 
design expert@. From the constructed DS, the working point was 
selected by visual examination looking for the least Rt of ambroxol and 
symmetric peak of levofloxacin. As per our method’s goal, at pH 4.5, % 
of acetonitrile 20% v/v, and flow rate of 1.2 ml/minute−1 satisfy faster 
separation (5.0) and optimum resolution between levofloxacin and 
ambroxol. Our objective was to maximize resolution with symmetric 
peak and to minimize analysis time.
Derringer’s desirability function
Hence, when there are multiple responses to optimize with different 
targets, derringer’s desirability function is a suitable technique. The 
derringer desirability (D) function is defined as the geometric mean, 
weighted, or otherwise, of the individual desirability functions. Value 
of D different from zero implies that all responses are in a desirable 
range simultaneously and consequently, for a value of D close to 
Table. 3: Regression model and statistical parameters obtained from ANOVA
Response Reduced regression model Adjusted R2 Model p % CV Adequate precision
Capacity factor Capacity factor =−50.13640+0.96433 * A+19.37499 
* B‑3.9844*C‑0.021796 *A2‑2.00964* B2
0.9030 0.0049 13.57 16.287
Resolution Resolution =−512.07167‑2.04740* A+175.19159 
* B+217.51185 * C+2.03891* A * C‑23.36426 * B * 
C‑15.12475 * B2−72.93594* C2
0.8025 0.0047 18.88 7.181
Last retension time Last retension time=+6.46787‑0.58223 * A‑0.50205 
*B+24.93415*C+0.55148* A*C‑21.3396* C2
0.8566 0.0020 6.46 7.374
Fig. 4: Chromatogram of levofloxacin and ambroxol hydrochloride
Table 2: Central composite rotatable design arrangement and responses






1 10 1 Axial 25.00 5.00 1.28 2.07 7.24 5.375
2 12 2 Center 25.00 5.00 1.00 2.9 12.4 6.825
3 9 3 Axial 25.00 5.00 0.72 4.4 5.875 9.442
4 15 4 Center 25.00 5.00 1.00 2.9 12.71 6.825
5 4 5 Fact 20.00 4.50 0.80 3.2 5.15 7.56
6 11 6 Center 25.00 5.00 1.00 2.9 12.3 6.725
7 2 7 Fact 30.00 4.50 1.20 0.72 13.40 3.24
8 3 8 Fact 20.00 5.50 1.20 1.2 5.32 4.25
9 7 9 Axial 25.00 4.29 1.00 2.91 4.42 6.95
10 6 10 Axial 32.07 5.00 1.00 1.02 15.42 7.25
11 14 11 Center 25.00 5.00 1.00 2.91 12.4 6.825
12 1 12 Fact 30.00 5.50 0.80 1.8 6.24 5.34
13 13 13 Center 25.00 5.00 1.00 2.91 12.4 6.825
14 8 14 Axial 25.00 5.71 1.00 1.52 5.24 6.24
15 5 15 Axial 17.93 5.00 1.00 3.24 15.54 7.25
Fig. 3: Overlay ultraviolet spectra of levofloxacin and ambroxol
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1 (0.92), the combination of the different criteria is globally optimal 
so that the response values are near target values. The criteria for 
the optimization of each response are shown in Table 4. Criteria have 
been proposed for selecting an optimum experimental condition for 
analyzing routine quality control samples. In general, a short analysis 
time is usually preferred for routine analysis. Hence, high importance 
(value 4) was assigned to Rt of last eluting peak. Following the 
conditions and restrictions above, the optimization procedure was 
carried out using design expect. The response surface plot obtained 
for the maximum desirability function (D=0.92) is presented in Fig. 6a, 
which indicates our mathematical model is excellent. The coordinates 
produce the maximum desirability value at acetonitrile 20 v/v, buffer 
pH 4.5, and flow rate of 1.2 ml/minute. The predicted response values 
corresponding to the above optimum condition are given in Table 3.
Method validation
Specificity: The specificity of the method was evaluated after analyzing 
the placebo containing both levofloxacin and ambroxol at a concentration 
of 1.0 µg ml−1 each. The selectivity of the method is depicted by the sharp 
well-resolved peaks for levofloxacin and ambroxol. The specificity of 
the method was checked by comparing the chromatograms obtained 
from standard, sample, and the corresponding placebo. The Rt of the 
standard and the drugs from sample solution were identical. This 
confirmed the specificity of the method.
Linearity: The linearity was established at the concentration range of 
1-10 µg ml−1 for levofloxacin and ambroxol. The standard stock solution 
was diluted with mobile phase to get 1, 2, 4, 6, 8, and 10 µg ml−1 of 
both levofloxacin and ambroxol. Each concentration was analyzed in 
3 replicates. Peak areas (y) of levofloxacin and ambroxol were plotted 
versus their respective concentrations (x), and linear regression 
analysis performed on the resultant calibration curves. Linearity data 
are shown in Table 5.
Accuracy/recovery accuracy of the method was determined by 
performing the recovery experiment at 80%, 100%, and 120% of the 
expected assay value or label claim of the drugs in the commercial 
tablet dosage form. To the standard drug solution, 4 µg ml−1 (80%), 
5 µg ml−1 (100%), and 6 µg ml−1 (120%) of both levofloxacin and 
ambroxol were added and analyzed by the proposed method in 3 
replicates at each level. The % mean recovery of drugs at each level was 
determined. The recoveries of levofloxacin and ambroxol at each level 
were found to lie well within the acceptable criteria of bias ±2% [32]. 
The accuracy result is shown in Table 6.
Limit of detection (LOD) and limit of quantification (LOQ) for both 
levofloxacin and ambroxol were determined according to the ICH 
guideline Q2 (R1) . LOD was defined as 3.3 r/S and LOQ as 10 r/S based 
on, standard deviation of the response (r) and slope of the calibration 
Fig. 5: Perturbation plot showing (a) the effect of each of the independent factors on capacity factor of both drugs, (b) the effect of each 
factor involved in  resolution between two drugs, (c) the effect of each of the independent factors on last retention time of ambroxol, while 




Table 4: Comparison of experimental and predictive values of different experimental runs under optimum conditions









Response 3 last 
retension time
20 ml 4.5 1.2 2.14 7.81 4.99
Experimental value
Predictive value 2.33 7.59 5.14
Predicted error 0.0102 0.0061 0.052
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curve (S) constructed at six levels ranging 1.0-10.0 µg ml−1 of both 
levofloxacin and ambroxol LOD and LOQ results are given in Table 5 are 
experimentally verified.
Precision: Precision was determined by studying the intermediate 
precision and repeatability. Repeatability expresses the precision under 
the same operating conditions over a short interval of time. Repeatability 
is also termed intra-assay precision. Intermediate precision expresses 
within-laboratories variations: Different days, different analysts, 
different equipment, etc. Intermediate precision is also termed inter-
assay precision. The intra- and inter-day assay precision was studied at 
2.0 µg ml−1 concentration level (n=5), and precision was confirmed as 
Table 6: Accuracy study using the proposed method
% level Amount added (µg mL-1) Amount found* in mg mL‑1 (Mean±S.D) % recovery* (Mean±S.D)
Levofloxacin Ambroxol Levofloxacin Ambroxol Levofloxacin Ambroxol
80 4 4 3.98±0.04 3.99±0.03 99.5±0.42 99.75±0.32
100 5 5 4.96±0.02 4.98±0.05 99.2±0.21 99.6±0.53
120 6 6 5.97±0.05 6.03±0.02 99.5±0.54 99.5±0.51
*Average of five determinations, SD: Standard deviation
Table 5: Parameters of linear regression equations for each drug compound
Parameters Levofloxacin* Ambroxol*
Calibration range (µg mL−1) 1-10 1-10
Correlation coefficient (r) 0.9998 0.9999
Slope 47922.21 64525.33
Intercept −230.92 4633.00
S.D of slope 258.29 320.69
S.D of intercept 1567.58 1946.31
LOD (µg mL−1) 0.097 0.092
LOQ (µg mL−1) 0.330 0.310
S.D: Standard deviation, LOD: Limit of detection, LOQ: Limit of quantification *average of six determinations
Fig. 6: 3‑D models shows (a) design space for the maximum derringer’s desirability function, (b) Design space for Resolution between 
Levofloxacin and ambroxol  in pH_% of acetonitrile model, (c) Design space for capacity factor between levofloxacin and ambroxol in 
pH_Flow rate model, (d) Design space for last retension time  of ambroxol drug  peak in pH_% of acetonitrile model
dc
ba
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Table 7: Intra‑ and Inter‑day precision for levofloxacin and ambroxol
S.N Intra day Inter day
Levofloxacin* Ambroxol* Levofloxacin* Ambroxol*
Area %recovery Area %recovery Area %recovery Area %recovery
1 47387 99.37 67489 98.41 47497 98.37 68438 98.88
2 47271 99.12 69271 100.18 47167 99.52 68209 98.53
3 47522 99.65 68918 99.63 48003 99.05 68438 98.88
4 47198 98.97 68926 99.64 47391 98.90 67927 98.09
5 46987 98.53 68948 99.67 47281 99.45 67581 97.56
SD 201.51 698.59 323.4 366.7
%RSD 0.426 1.01 0.681 0.538
*Average of five determinations, SD: Standard deviation, RSD: Relative stratigraphic depth
the % relative stratigraphic depth was well within the target criterion 
(of the assay results was <2%, which indicates the method is precise. 
The precision data are shown in Table 7, and the values are complied 
the limits as per IP standard.
CONCLUSION
Statistically based experimental designs proved to be an important 
approach in optimizing selectivity-controlling parameters for the 
simultaneous determination of levofloxacin and ambroxol in commercial 
formulation. The significant factors were optimized by applying central 
composite design and RSM. The objective of responses is resolution, 
capacity factor, and the analysis time simultaneously optimized by 
applying (derringer’s desirability function) a multi-criteria decision-
making tool. This method has been evaluated for linearity, precision, 
accuracy, and selectivity and has proved to be convenient and effective 
for the quality control of levofloxacin and ambroxol in raw material and 
its formulations. Moreover, the previously reported method addresses 
only separation of both drugs with the traditional approach with longer 
run time of >10.0 minutes by using 150 mm length columns (5 µm 
particle size) while our proposed method is able to quantify levofloxacin 
and ambroxol within a run time of 5 minutes.
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